Business Context and Reporting Period
Company: Bausch + Lomb Corporation (BLCO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Overview: Bausch + Lomb is a leading global eye health company operating in three segments: Vision Care, Pharmaceuticals, and Surgical. The company remains a subsidiary of Bausch Health Companies Inc. (BHC), which holds approximately 88.2% of outstanding shares. The full separation from BHC is contingent upon achieving targeted debt leverage ratios and receiving necessary approvals.
Key Financial Metrics
| Metric (in millions) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Total Revenues | $1,216 | $1,035 | $2,315 | $1,966 |
| Operating Income | $26 | $43 | $32 | $41 |
| Net Loss (Attributable to B+L) | $(151) | $(32) | $(318) | $(122) |
| Diluted Loss Per Share | $(0.43) | $(0.09) | $(0.90) | $(0.35) |
| Operating Cash Flow (6M) | $56 | $(80) | $56 | $(80) |
| Total Debt (Principal) | $4,696 | N/A | $4,696 | N/A |
| Cash & Equivalents | $285 | N/A | $285 | N/A |
Note: Debt figures represent principal amounts outstanding as of June 30, 2024. Operating cash flow is presented for the six-month period.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 17% in Q2 2024 and 18% in the first six months of 2024 compared to the prior year. Growth was driven by acquisitions (specifically XIIDRA and Blink), increased volumes, and higher net realized pricing.
- Segment Performance:
- Pharmaceuticals: Revenue surged 60% in Q2 and 63% in 6M, primarily due to the inclusion of XIIDRA (acquired Sept 2023) and the launch of MIEBO.
- Vision Care: Revenue grew 8% in Q2 and 8% in 6M, driven by dry eye portfolio sales (Lumify, PreserVision) and contact lens volumes.
- Surgical: Revenue grew 7% in Q2 and 7% in 6M, supported by increased demand for consumables and premium IOLs.
- Profitability Pressure: Despite revenue growth, Operating Income declined 40% in Q2 and 22% in 6M. This was caused by a significant increase in Selling, General, and Administrative (SG&A) expenses (up 28% in Q2) and Amortization of intangible assets (up 32% in Q2), alongside higher interest expenses.
- Interest Expense: Interest expense more than doubled in the six-month period (from $108M to $201M) due to new debt facilities incurred to finance the XIIDRA acquisition.
- Provisions: Rebates and other provisions increased as a percentage of gross sales (from 29.1% to 35.4% in Q2), largely attributable to the rebate structures of XIIDRA and MIEBO.
Guidance, Outlook, Risks, and Unusual Items
- Separation from BHC: The company continues to pursue a spin-off from BHC. Completion is subject to achieving targeted debt leverage ratios. Management expects to refinance debt upon full separation.
- Acquisitions:
- XIIDRA: Acquired in Sept 2023 for $1.75B; now a major revenue driver in the Pharmaceuticals segment.
- Trukera Medical: Acquired in July 2024 (post-period) to expand dry eye diagnostics.
- Debt and Liquidity: The company carries significant debt ($4.7B principal) with a weighted average interest rate of 8.63%. It remains in compliance with financial covenants. Management expects to meet debt service obligations for the next 12 months.
- Legal Proceedings:
- Antitrust: Ongoing multidistrict litigation regarding generic pharmaceutical pricing.
- Product Liability: Pending lawsuits regarding Shower to Shower talc products (indemnified by Johnson & Johnson).
- Intellectual Property: Active litigation defending patents for Lumify and PreserVision against generic competitors.
- Geopolitical Risks: Ongoing conflicts in Russia/Ukraine and the Middle East pose risks to operations, though current revenue exposure in these regions is limited (approx. 3% for Russia/Ukraine/Belarus).
- Unusual Items: Q2 2024 included $5M in asset impairments related to a product brand discontinuation and $6M in restructuring costs.
Investor Verification Checklist
- Debt Leverage Ratios: Verify the company's progress toward the targeted leverage ratios required to trigger the separation from BHC.
- Rebate Impact: Monitor the sustainability of the increased rebate provisions (now ~36% of gross sales) and their impact on net margins.
- Interest Rate Exposure: Assess the impact of floating-rate debt (SOFR-based) on future interest expenses given the current high-rate environment.
- Patent Litigation Outcomes: Track the status of Paragraph IV proceedings for Lumify and PreserVision, as generic entry could materially impact future revenues.
- Integration Costs: Review the trajectory of SG&A expenses to ensure they stabilize as the XIIDRA and Blink acquisitions are fully integrated.